Anne Lok

Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life

Clara Sortais, Anne Lok, Benoît Tessoulin et al. · Annals of Hematology · 2020 · 48 citations

Medicine, Hematology, Oncology +8

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

A. Lassalle, P. Thomaré, Clémentine Fronteau et al. · Annals of Oncology · 2015 · 45 citations

Medicine, Oncology, Pharmacotherapy +12

Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients

Patrice Chevallier, Marianne Coste‐Burel, Amandine Le Bourgeois et al. · eJHaem · 2021 · 39 citations · Full text

Veterinary Medicine, Biomedical Sciences, Immunology +16

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 ⁺ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Thibaut Leguay, Marc Delord, Cyril Šálek et al. · Journal of Clinical Oncology · 2024 · 34 citations

Medicine, Hematology, Oncology +16

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

Maxime Jullien, Sabrina Trudel, Benoît Tessoulin et al. · Annals of Hematology · 2019 · 33 citations

Medicine, Oncology, Pharmacotherapy +13